The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
The company is moving towards complex and more differentiated products
It’s an AB-rated generic therapeutic version of Durezol
Workshop focused on strengthening sterile processing standards, infection prevention, and CSSD best practices in healthcare settings
The centre will leverage AI-enabled tools to support research and diagnostics for complex eye–brain disorders
Targets high-growth eye care expansion push
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
Subscribe To Our Newsletter & Stay Updated
